Diversify Wealth Management LLC Buys 2,924 Shares of Ascendis Pharma A/S $ASND

Diversify Wealth Management LLC boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 37.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 10,675 shares of the biotechnology company’s stock after buying an additional 2,924 shares during the period. Diversify Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $2,352,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ASND. Ferguson Wellman Capital Management Inc. bought a new position in Ascendis Pharma A/S during the first quarter valued at $595,000. Candriam S.C.A. increased its stake in Ascendis Pharma A/S by 23.2% in the 1st quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock worth $52,671,000 after buying an additional 43,338 shares during the period. Personal CFO Solutions LLC increased its stake in Ascendis Pharma A/S by 4.4% in the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock worth $347,000 after buying an additional 64 shares during the period. Leonteq Securities AG lifted its holdings in Ascendis Pharma A/S by 405.9% during the 1st quarter. Leonteq Securities AG now owns 855 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 686 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in Ascendis Pharma A/S by 243.0% during the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock valued at $56,907,000 after buying an additional 178,415 shares in the last quarter.

Ascendis Pharma A/S Trading Down 1.9%

NASDAQ ASND opened at $265.22 on Tuesday. Ascendis Pharma A/S has a 52 week low of $160.86 and a 52 week high of $282.15. The company has a 50 day moving average price of $240.71 and a 200 day moving average price of $230.69. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The firm has a market cap of $16.54 billion, a PE ratio of 30.59 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post 4.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ASND shares. Wedbush reissued an “outperform” rating and issued a $273.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Wells Fargo & Company decreased their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a report on Monday, March 16th. They issued a “buy” rating and a $290.00 price target for the company. Royal Bank Of Canada raised their price objective on Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Evercore reiterated an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $295.67.

Insiders Place Their Bets

In other news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jean Jacques Bienaime bought 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the purchase, the director owned 400 shares in the company, valued at $95,120. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 40.00% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.